BioNexus Gene Lab Corp (BGLC): Nasdaq/NYSE listing notice — BioNexus Gene Lab gets Nasdaq extension to May 1, 2025 for bid price compliance; plans reverse split

BioNexus Gene Lab Corp

Nasdaq Hearings Panel grants temporary exception until May 1, 2025 to regain minimum $1.00 bid price.
Company intends to effect a reverse stock split by April 7, 2025 if needed.
Effective Jan 30, 2025, Nasdaq requires 10-day prior notice of reverse split details, including shareholder approval date.
Failure to comply by May 1, 2025 will result in delisting from Nasdaq Capital Market.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

BioNexus Gene Lab Corp received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

December 27, 2024, BioNexus Gene Lab Corp. (the “Company”) received a written notice from the Nasdaq Hearings Panel (the “Panel”) indicating that the Company has been granted a temporary exception to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share (the “Bid Price Rule”). The Company has until May 1, 2025, to regain compliance. As part of this compliance plan, the Company intends to effect a reverse stock split, if necessary, no later than April 7, 2025, and has outlined steps to meet this timeline. Failure to regain compliance by May

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

BioNexus Gene Lab Corp filing history →

Source: SEC EDGAR

accession 0001477932-25-000006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.